Aliases & Classifications for Inner Ear Disease

MalaCards integrated aliases for Inner Ear Disease:

Name: Inner Ear Disease 12 14
Labyrinthine Dysfunction 12 14 69
Labyrinthine Disorder 69
Diseases of Inner Ear 69
Labyrinthine Disease 12
Labyrinth Diseases 42

Classifications:



Summaries for Inner Ear Disease

MalaCards based summary : Inner Ear Disease, also known as labyrinthine dysfunction, is related to autoimmune inner ear disease and bilateral hyperactive labyrinth, and has symptoms including earache and vertigo. An important gene associated with Inner Ear Disease is FGF3 (Fibroblast Growth Factor 3), and among its related pathways/superpathways are Gap junction trafficking and Rheumatoid arthritis. The drugs Betahistine and Histamine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and liver, and related phenotypes are homeostasis/metabolism and hearing/vestibular/ear

Related Diseases for Inner Ear Disease

Diseases related to Inner Ear Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 76)
id Related Disease Score Top Affiliating Genes
1 autoimmune inner ear disease 12.3
2 bilateral hyperactive labyrinth 10.9
3 unilateral hyperactive labyrinth 10.9
4 bilateral hypoactive labyrinth 10.9
5 spastic paraparesis and deafness 10.9 FADD FGF3
6 autoimmune oophoritis 10.9 MPO TNF
7 myocardial infarction 2 10.9 GJB2 GJB6
8 myopia 22, autosomal dominant 10.8 GJB2 GJB6
9 transient neonatal multiple acyl-coa dehydrogenase deficiency 10.8 GJB2 GJB3
10 migraine with brainstem aura 10.8 MPO TNF
11 spondylocostal dysostosis 4 10.7 B2M TNF
12 primary biliary cirrhosis 10.7 B2M FADD TNF
13 deafness, autosomal dominant 3a 10.7 GJB2 GJB3 GJB6
14 kikuchi disease 10.7 GJB2 GJB3 GJB6
15 pseudocholinesterase deficiency 10.7 GJB2 GJB3 GJB6
16 diabetes persistent mullerian ducts 10.6 GJB2 GJB6 MYO7A
17 erythrokeratodermia variabilis et progressiva 1 10.6 GJB2 GJB3 GJB6
18 fibrosis of extraocular muscles, congenital, 2 10.6 FGF3 GJB2 MYO7A
19 dementia, familial british 10.6 GJB2 GJB3 GJB6
20 troyer syndrome 10.6 GJB2 GJB6
21 anencephaly and spina bifida x-linked 10.6 MPO TNF
22 congenital disorder of glycosylation with developmental anomaly 10.6 GJB2 GJB6 MT-RNR1
23 cataract 26, multiple types 10.6 GJB2 MT-RNR1 SLC26A4
24 megalocytic interstitial nephritis 10.6 ATP6V0A4 ATP6V1B1
25 deafness, autosomal dominant 36 10.5 GJB2 MT-RNR1
26 deafness, autosomal recessive 37 10.5 COCH MYH9 MYO7A
27 hypogonadotropic hypogonadism 10.5 ATP6V0A4 B2M
28 sengers syndrome 10.5 ATP6V0A4 ATP6V1B1
29 ausems wittebol-post hennekam syndrome 10.5 GJB2 GJB6 MT-RNR1
30 leber congenital amaurosis 14 10.5 CDH23 GJB2 SLC26A4
31 akaba hayasaka syndrome 10.5 B2M TNF
32 deafness, autosomal recessive 53 10.5 COCH GJB2 MYO7A SLC26A4
33 nonsyndromic hydrocephalus, ccdc88c-related 10.5 COCH GJB2 GJB6 KCNQ4
34 deafness, autosomal dominant 2a 10.5 COCH GJB2 GJB6 KCNQ4
35 small non-cleaved cell lymphoma 10.5 GJB2 GJB3 GJB6 TNF
36 renier gabreels jasper syndrome 10.4 ATP6V0A4 ATP6V1B1
37 bifid nose with or without anorectal and renal anomalies 10.4 CDH23 MYO7A SLC26A4
38 ectodermal dysplasia 6, hair/nail type 10.4 CDH23 MYO7A SLC26A4
39 exocrine pancreatic insufficiency 10.4 COL4A5 MYH9 TNF
40 calcinosis 10.4 ATP6V0A4 B2M TNF
41 deafness, autosomal recessive 23 10.3 COCH MYO7A
42 microcephaly and chorioretinopathy, autosomal recessive, 3 10.3 COCH GJB2 GJB6 MYO7A SLC26A4
43 hyperphenylalaninemia, mild, non-bh4-deficient 10.3 CDH23 GJB2 MYO7A SLC26A4
44 pituitary adenoma 10.3 CDH23 GJB2 MYO7A SLC26A4
45 fascioliasis 10.2 GJB2 GJB3 GJB6 MT-RNR1 SLC26A4
46 keratoderma, palmoplantar, with deafness 10.2 GJB2 GJB6
47 severe combined immunodeficiency, athabascan type 10.1 GJB2 MT-RNR1 MYH9 MYO7A SLC26A4
48 autosomal genetic disease 10.1 ATP6V0A4 ATP6V1B1 SLC19A2 SLC26A4
49 congenital muscular dystrophy due to lmna mutation 10.1 CDH23 COCH GJB2 MYO7A SLC26A4
50 chronic myelomonocytic leukemia 10.1 B2M COL4A5 MYH9

Comorbidity relations with Inner Ear Disease via Phenotypic Disease Network (PDN):


Hypertension, Essential Ischemic Heart Disease
Labyrinthitis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Inner Ear Disease:



Diseases related to Inner Ear Disease

Symptoms & Phenotypes for Inner Ear Disease

UMLS symptoms related to Inner Ear Disease:


earache, vertigo

MGI Mouse Phenotypes related to Inner Ear Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.16 ATP6V0A4 ATP6V1B1 B2M CDH23 COL4A5 FADD
2 hearing/vestibular/ear MP:0005377 10.1 CDH23 COCH FGF3 GJB2 GJB6 KCNQ4
3 cardiovascular system MP:0005385 10.07 RTEL1 TNF B2M COL4A5 FADD GJB2
4 immune system MP:0005387 9.93 FGF3 GJB2 GJB3 GJB6 MPO MYH9
5 nervous system MP:0003631 9.77 B2M CDH23 FADD FGF3 GJB2 GJB6
6 no phenotypic analysis MP:0003012 9.23 FADD FGF3 GJB2 GJB3 GJB6 MYH9

Drugs & Therapeutics for Inner Ear Disease

Drugs for Inner Ear Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Betahistine Approved Phase 4 5638-76-6 2366
2
Histamine Approved, Investigational Phase 4,Phase 3 75614-87-8, 51-45-6 774
3
Dimenhydrinate Approved Phase 4,Phase 3 523-87-5 441281
4 Piracetam Approved Phase 4 7491-74-9
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
7
Ethanol Approved Phase 4 64-17-5 702
8
Glycerol Approved, Investigational Phase 4 56-81-5 753
9
Phenol Approved, Experimental Phase 4 108-95-2 996
10
Thymol Approved Phase 4 89-83-8 6989
11
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
12
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
15
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
16
Ondansetron Approved Phase 4 99614-02-5 4595
17
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
18
Calcium Carbonate Approved Phase 4 471-34-1
19
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
20
Glucosamine Approved, Nutraceutical Phase 4 3416-24-8 439213
21
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
23
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
24
Nicotinamide Approved, Nutraceutical Phase 4 98-92-0 936
25 Tocopherol Approved, Nutraceutical Phase 4
26
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
27
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
28
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
29
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
30 Anticoagulants Phase 4
31 Antimetabolites Phase 4,Phase 3
32 Fibrinolytic Agents Phase 4
33 Glucuronyl glucosamine glycan sulfate Phase 4
34 Hypoglycemic Agents Phase 4
35 Hypolipidemic Agents Phase 4
36 Lipid Regulating Agents Phase 4
37 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
38 Anti-Infective Agents Phase 4,Phase 2,Phase 3
39 Antiviral Agents Phase 4,Phase 2,Phase 3
40 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
41
Histamine Phosphate Phase 4,Phase 3 51-74-1 65513
42 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Vasodilator Agents Phase 4,Phase 2,Phase 1
44 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
45 Central Nervous System Stimulants Phase 4
46 Phosphodiesterase Inhibitors Phase 4,Phase 2
47 Purinergic P1 Receptor Antagonists Phase 4
48 Antiemetics Phase 4,Phase 2,Phase 3
49 Antioxidants Phase 4,Phase 1,Phase 2
50 Autonomic Agents Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 188)

id Name Status NCT ID Phase Drugs
1 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients Unknown status NCT00132223 Phase 4 Contrast agent
2 Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy Completed NCT00160238 Phase 4 Betahistine 24 mg bid (Betaserc)
3 Efficacy of Local Overpressure Treatment for Meniere's Disease Completed NCT00831688 Phase 4
4 Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets Completed NCT02718846 Phase 4 Meniace;Isobide
5 Effect of Caffeine Intake in Vestibular Function Completed NCT02825199 Phase 4
6 Effect of Stellate Ganglion Block on Meniere's Disease Completed NCT01574313 Phase 4 0.25mg, fludiazine;25mg cephadol@ (diphenidol);200mg kentons@ (tocopherol nicotinate).
7 Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo Completed NCT01890538 Phase 4 Administration of 100 mg dimenhydrinate intravenous;2 g piracetam intravenous
8 Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo Completed NCT02253524 Phase 4 Dimenhydrinate;Metoclopramide
9 Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal Completed NCT00765635 Phase 4 drops intilation (Taponoto ® );drops intilation (Otocerum®);drops intilation (Placebo)
10 Efficacy of Acetylcysteine in Patients Undergoing Surgery for Otosclerosis Completed NCT00525551 Phase 4 Acetylcysteine;Placebo (NaCl)
11 Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment Completed NCT01372904 Phase 4 Dexamethasone Phosphate
12 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease Recruiting NCT02530931 Phase 4 Gadolinium
13 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS) Recruiting NCT02529475 Phase 4 Gadoteric acid
14 Acute Unilateral Vestibulopathy and Corticosteroid Treatment Recruiting NCT02912182 Phase 4 Betamethasone;Placebo;Prednisolone
15 Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV Recruiting NCT02031692 Phase 4 400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate
16 Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery Recruiting NCT02724033 Phase 4 Antiemetic
17 A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation Withdrawn NCT00474409 Phase 4 Merislon
18 Audiometric Parameters in Conductive Hearing Loss and Middle Ear Disease Unknown status NCT00222417 Phase 2, Phase 3
19 Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease Unknown status NCT01729767 Phase 2, Phase 3 Acyclovir;Placebo
20 Conventional Versus Virtual Reality Based Vestibular Rehabilitation Completed NCT01442623 Phase 2, Phase 3
21 Study of Lamotrigine to Treat Ménière's Disease Completed NCT02158585 Phase 3 Lamotrigine;Placebo
22 Study of OTO-104 in Subjects With Unilateral Meniere's Disease Completed NCT02612337 Phase 3 OTO-104;Placebo
23 Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease Completed NCT00802529 Phase 2, Phase 3 Methylprednisolone;Gentamicin
24 Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease Completed NCT01454726 Phase 3
25 Balance Training in Parkinson's Disease Using Cues Completed NCT01960985 Phase 3
26 AM-111 in the Treatment of Acute Inner Ear Hearing Loss Completed NCT02561091 Phase 3 AM-111 0.4 mg/ml;AM-111 0.8 mg/ml
27 The Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo Completed NCT02029508 Phase 3
28 Promethazine vs. Lorazepam for Treatment of Vertigo Completed NCT01827293 Phase 3 Promethazine;Lorazepam
29 Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT01366430 Phase 3
30 Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT00810641 Phase 3
31 Canalith Repositioning Procedure for BPPV in Primary Care Completed NCT00182273 Phase 3
32 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
33 Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin Recruiting NCT02112578 Phase 3 Meclizine;Dimenhydrinate
34 Rizatriptan for Episodic Dizziness in Vestibular Migraine Recruiting NCT02447991 Phase 2, Phase 3 Rizatriptan;Placebo
35 Caroverin and Inner Ear Diseases Suspended NCT01174979 Phase 3 Caroverin
36 Autoimmunity in Inner Ear Disease Terminated NCT00000361 Phase 3 Corticosteroids;Methotrexate
37 Famvir for Treatment of Hearing in Unilateral Meniere's Disease Terminated NCT01526408 Phase 3 Famciclovir;Placebo
38 Study of OTO-104 in Subjects With Unilateral Meniere's Disease Terminated NCT02717442 Phase 3 OTO-104;Placebo
39 A 6-Month Extension Study of OTO-104 in Meniere's Disease Terminated NCT02768662 Phase 3 OTO-104
40 A 6-Month Extension Study of OTO-104 in Meniere's Disease Terminated NCT02706730 Phase 3 OTO-104
41 Therapeutic Efficacy of Tiludronic Acid on Inner Ear Involvement in Advanced Otosclerosis Terminated NCT01617057 Phase 3 tiludronic acid;Placebo
42 Visual Feedback Goggle for Positional Vertigo Treatment Unknown status NCT00729885 Phase 1, Phase 2
43 Efficacy of Extended-release, Once Daily Tramadol for Post Operative Analgesia in Shoulder Arthroscopy Unknown status NCT02247648 Phase 2 tramadol;Placebo
44 A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Completed NCT01267994 Phase 1, Phase 2 Anakinra
45 The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease Completed NCT01950312 Phase 2 gevokizumab
46 Sildenafil For Meniere's Disease Completed NCT00145483 Phase 2 Sildenafil
47 OTO-104 for the Treatment of Meniere's Disease Completed NCT01412177 Phase 2 OTO-104;Placebo
48 Study to Evaluate SPI-1005 in Adults With Meniere's Disease Completed NCT02603081 Phase 1, Phase 2 SPI-1005
49 A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom Completed NCT02265393 Phase 2 OTO-104;Placebo
50 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone

Search NIH Clinical Center for Inner Ear Disease

Cochrane evidence based reviews: labyrinth diseases

Genetic Tests for Inner Ear Disease

Anatomical Context for Inner Ear Disease

MalaCards organs/tissues related to Inner Ear Disease:

39
Testes, Brain, Liver, Bone, Eye, Pons, Lung

Publications for Inner Ear Disease

Articles related to Inner Ear Disease:

(show top 50) (show all 128)
id Title Authors Year
1
The Balance of Tissue Inhibitor of Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Autoimmune Inner Ear Disease Patients. ( 28696822 )
2017
2
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. ( 26885370 )
2016
3
Chronic cerebrospinal venous insufficiency as a cause of inner ear diseases. ( 27846752 )
2016
4
N-Acetylcysteine attenuates tumor necrosis factor alpha levels in autoimmune inner ear disease patients. ( 26392121 )
2015
5
Current understanding of the pathogenesis of autoimmune inner ear disease: a review. ( 25847404 )
2015
6
Paraneoplastic syndrome: a masquerade of autoimmune inner ear disease. ( 25427223 )
2015
7
Systematic Review of Treatments for Autoimmune Inner Ear Disease. ( 26485595 )
2015
8
Progression of autoimmune inner ear disease to labyrinthitis ossificans: clinical and radiologic correlation. ( 25738715 )
2015
9
Diffuse systemic sclerosis presenting as Meniere's disease-like symptoms as part of autoimmune inner ear disease. ( 26040060 )
2015
10
The role of intracochlear drug delivery devices in the management of inner ear disease. ( 25347140 )
2014
11
An open label study to evaluate the safety and efficacy of intratympanic golimumab therapy in patients with autoimmune inner ear disease. ( 25203561 )
2014
12
IL-1I^ inhibition in autoimmune inner ear disease: can you hear me now? ( 25133418 )
2014
13
Cochlin in autoimmune inner ear disease: Is the search for an inner ear autoantigen over? ( 25199741 )
2014
14
New prospects in the diagnosis and treatment of immune-mediated inner ear disease. ( 25332908 )
2014
15
Ocular vestibular evoked myogenic potentials induced by bone-conducted vibration in patients with unilateral inner ear disease. ( 24215219 )
2014
16
Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease. ( 25133431 )
2014
17
Autoimmune inner ear disease: a retrospective review of forty-seven patients. ( 23817208 )
2013
18
Review of the biologic agents used for immune-mediated inner ear disease. ( 22770424 )
2013
19
Cogan's syndrome: an autoimmune inner ear disease. ( 22846458 )
2013
20
Autoimmune inner ear disease preliminary case report: audiometric findings following steroid treatments. ( 23800807 )
2013
21
Innate immune recognition of molds and homology to the inner ear protein, cochlin, in patients with autoimmune inner ear disease. ( 23912888 )
2013
22
Developments in delivery of medications for inner ear disease. ( 23560526 )
2013
23
Infliximab for autoimmune inner ear disease: case report and literature review. ( 24125068 )
2013
24
Spectrum of immune-mediated inner ear disease and cochlear implant results. ( 22991211 )
2012
25
A pilot study of rituximab in immune-mediated inner ear disease. ( 20980741 )
2011
26
High dose combination pertussis toxin induces autoimmune inner ear disease in Sprague-Dawley rats. ( 21366505 )
2011
27
Autoimmune inner ear disease in children. ( 21178803 )
2011
28
Auditory and vestibular hair cell stereocilia: relationship between functionality and inner ear disease. ( 21774850 )
2011
29
IL-1I^ is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. ( 21199898 )
2011
30
Inner ear disease and benign paroxysmal positional vertigo: a critical review of incidence, clinical characteristics, and management. ( 21837242 )
2011
31
Development of gene therapy for inner ear disease: Using bilateral vestibular hypofunction as a vehicle for translational research. ( 21251965 )
2011
32
Extraintestinal Crohn's disease mimicking autoimmune inner ear disease: a histopathological approach. ( 20523038 )
2011
33
Cochlear implantation outcomes in patients with autoimmune and immune-mediated inner ear disease. ( 20729775 )
2010
34
Cochlear implantation in patients with autoimmune inner ear disease including cogan syndrome: a comparison with age- and sex-matched controls. ( 21082747 )
2010
35
Dr. Takeda's research on MAcniA"re disease and inner ear disease. Preface. ( 20185942 )
2010
36
Guest editorial: drug delivery for treatment of inner ear disease: current state of knowledge. ( 20215911 )
2010
37
Benign paroxysmal positional vertigo secondary to inner ear disease. ( 20723780 )
2010
38
Drug delivery for treatment of inner ear disease: current state of knowledge. ( 19952751 )
2010
39
Labyrinthitis ossificans secondary to autoimmune inner ear disease: a previously unreported condition. ( 20416474 )
2010
40
Induction of tolerance by oral administration of beta-tubulin in an animal model of autoimmune inner ear disease. ( 19365153 )
2009
41
Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease. ( 19395984 )
2009
42
The diagnosis of autoimmune inner ear disease: evidence and critical pitfalls. ( 18777037 )
2009
43
Immunosuppressive therapy for autoimmune inner ear disease. ( 19885385 )
2009
44
Autoimmune inner ear disease: clinical and laboratory findings and treatment outcome. ( 19128599 )
2008
45
A novel controlled local drug delivery system for inner ear disease. ( 18182968 )
2008
46
Does the serological study for viral infection in autoimmune inner ear disease make sense? ( 18235201 )
2008
47
Recurrent autoimmune inner ear disease (AIED) and polyarteritis nodosa in a patient with large cell lung carcinoma. ( 16552463 )
2007
48
SNP genome scanning localizes oto-dental syndrome to chromosome 11q13 and microdeletions at this locus implicate FGF3 in dental and inner-ear disease and FADD in ocular coloboma. ( 17656375 )
2007
49
Topical ocular drug delivery to inner ear disease and sinusitis. ( 17195427 )
2006
50
Immune-mediated inner ear disease. ( 16923703 )
2006

Variations for Inner Ear Disease

Expression for Inner Ear Disease

Search GEO for disease gene expression data for Inner Ear Disease.

Pathways for Inner Ear Disease

Pathways related to Inner Ear Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.12 GJB2 GJB3 GJB6
2 10.75 ATP6V0A4 ATP6V1B1 TNF
3 10.36 MPO TNF

GO Terms for Inner Ear Disease

Cellular components related to Inner Ear Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.55 ATP6V0A4 ATP6V1B1 GJB6 MYO7A SLC26A4
2 vacuolar proton-transporting V-type ATPase complex GO:0016471 9.26 ATP6V0A4 ATP6V1B1
3 gap junction GO:0005921 9.13 GJB2 GJB3 GJB6
4 connexin complex GO:0005922 8.8 GJB2 GJB3 GJB6

Biological processes related to Inner Ear Disease according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 inner ear morphogenesis GO:0042472 9.61 ATP6V1B1 KCNQ4 MYO7A
2 inner ear development GO:0048839 9.54 GJB2 GJB6 MYO7A
3 negative regulation of growth of symbiont in host GO:0044130 9.51 MPO TNF
4 actin filament-based movement GO:0030048 9.49 MYH9 MYO7A
5 sensory perception of light stimulus GO:0050953 9.48 CDH23 MYO7A
6 positive regulation of T cell mediated cytotoxicity GO:0001916 9.46 B2M FADD
7 death-inducing signaling complex assembly GO:0071550 9.4 FADD TNF
8 cell communication GO:0007154 9.33 GJB2 GJB3 GJB6
9 necroptotic signaling pathway GO:0097527 9.32 FADD TNF
10 sensory perception of sound GO:0007605 9.28 ATP6V0A4 ATP6V1B1 CDH23 COCH GJB2 GJB6
11 equilibrioception GO:0050957 9.26 CDH23 MYO7A
12 regulation of pH GO:0006885 9.13 ATP6V0A4 ATP6V1B1 SLC26A4

Molecular functions related to Inner Ear Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 microfilament motor activity GO:0000146 9.16 MYH9 MYO7A
2 gap junction channel activity GO:0005243 8.96 GJB2 GJB3
3 actin-dependent ATPase activity GO:0030898 8.62 MYH9 MYO7A

Sources for Inner Ear Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....